Sri Balaji University Pune offers MBA and BBA programs in Full Time mode. Sri Balaji University Pune Courses and Programs, ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Biogen Inc. closed $107.72 short of its 52-week high ($259.93), which the company achieved on January 5th.

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight to ...

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.

Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, ...

Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a significant decrease in short interest in the month of ...

As we enter the new year, all eyes are on the biotech companies awaiting key FDA decisions in January. In 2024, the FDA approved 50 ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have received an average rating of “Hold” from the twenty-nine ...

MOR-210 is under clinical development by Biogen and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition success ...